
#biotech
11 articles


Healthcare Sector
FDA H2 2026 Oncology Docket Packs Four Major Decisions Into One Catalyst Window
Via News Editorial Team•

Healthcare Sector
GRAIL Shares Slide 20% After NHS Trial Miss Puts Galleri's FDA Path in Doubt
Via News Editorial Team•


Equities Risk
Vectus Biosystems faces delisting risk as asset sale proceeds may fall short of operational needs
ViaNews Editorial Team (Markets)•

Healthcare Equities
Jade Biosciences JADE301 Phase 1 Trial Set for March 2027 Start in Autoimmune Space
ViaNews Editorial Team (Markets)•


Analysis
Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle
ViaNews Editorial Team (Markets)•

Technology
Illumina Q4 Earnings: Can Genomics Leader Sustain Growth?
ViaNews Editorial Team (Markets)•

Technology
Guardant Health Reports Strong Q4 Revenue Growth Amid Market Competition
ViaNews Editorial Team (Markets)•
